FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA
FDA finalized a post-market assessment program for food chemicals and announced reassessment of BHT and ADA. While focused on food, this signals increased scrutiny of chemical safety that may extend to cosmetics under MoCRA, particularly for ingredients used in both food and personal care.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors using BHT or ADA in cosmetics should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; reassessment timeline not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is reassessing the safety of BHT and ADA in food, which may lead to future restrictions or additional safety data requirements for cosmetics containing these ingredients.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors using BHT or ADA in cosmetics
What you must do
Monitor FDA's reassessment outcomes and consider proactive safety substantiation for products containing BHT or ADA.
Deadline
No immediate deadline; reassessment timeline not specified.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection